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Parkinson’s disease (PD) is a chronic, neurodegenerative disorder.1 PD arises as a result of the progressive loss of midbrain dopaminergic (mDA) neurons in the substantia nigra.2 Degeneration of these neurons leads to a decrease in dopamine concentration in the striatum, although other areas may also be affected.3 Dopamine is an important catecholamine neurotransmitter in the brain of mammals.4 It regulates a number of functions including cognition, emotion, food intake, positive reinforcement, endocrine regulation and locomotor activity.4 Dopamine plays numerous roles in the periphery of the body as well, for example in cardiovascular and renal function.4 Dopamine acts by activating dopamine receptors, of which several subtypes exist.4 Dopaminergic neurons in the substantia nigra that project into the striatum give rise to the nigrostriatal pathway (figure 1).4 The striatum controls motor function through activation of dopamine receptors.4 As much as 80% of the mDA neurons within the substantia nigra have been lost by the time symptoms first appear.3 Symptoms generally consist of motor problems, including resting tremor, bradykinesia or akinesia, muscle rigidity and postural instability.3 
It is commonly known that the prevalence of PD increases with age.5 It is hard to estimate the exact prevalence of PD and a lot of studies exclude the population below the age of 40 years, where the prevalence is lower.5 A study in the Netherlands found a prevalence of 6 per 1000 people in those between the age of 65 and 69 years and 26 per 1000 people in those aged 85 to 90 years.5 The prevalence of PD in the general population worldwide varies, with for example a prevalence of 57 per 100,000 people in China and 371 per 100,000 people in Sicily.5
PD is not fatal by itself.5 Nevertheless, PD results in physical disabilities that predispose patients to pneumonia, pulmonary embolism, deep venous thrombosis, falls and consequential complications.5 Furthermore, the severity of the symptoms significantly lowers the quality of life of the patient.3
Besides the negative impact of PD on the patient’s life, PD is also an economic burden. It has been estimated that the total direct costs of PD in Europe were 10.7 billion euro’s in 2004.3								Figure 1: Nigrostriatal pathway6

1.2 A treatment for Parkinson’s disease?
At present, there is no cure for PD.3 Current treatment focuses on the relief of symptoms and maintenance of the patient’s quality of life, independence and mobility.3 So far, pharmacological treatment is mainly based on increasing the amount of dopamine available for the striatum in order to reduce motor problems.3 Unfortunately, it is not possible to administer dopamine itself to the patient as a treatment, because dopamine is unable to cross the blood-brain barrier.7

For that reason, levodopa (L-dopa) has been the ‘golden standard’ in drug therapy for a long time.3 L-dopa is a dopamine precursor, which is transformed to dopamine in the neurons projecting from the substantia nigra to the striatum.3 This way, the availability of dopamine in the striatum is increased.3 L-dopa is often administered in combination with carbidopa, which facilitates the accessibility of L-dopa into the brain.3 Treatment with L-dopa however, has limitations; patients treated with L-dopa at high doses for a long time are likely to develop motor fluctuations and dyskinesias.3 Therefore, other drugs are often used to diminish the use of L-dopa.3 Catechol-O-methyltransferase (COMT) inhibitors for example, are able to lengthen the clinically effective period of L-dopa.3 COMT is an enzyme which degrades dopamine and L-dopa in the periphery of the body.7 COMT inhibitors provide a higher level of L-dopa in the plasma, thereby allowing a decrease in the drug dosage of L-dopa.7 The problem is that COMT inhibitors combined with L-dopa enhance dopaminergic side effects, such as hallucinations, nausea or dyskinesias.3 Dopamine agonists are also administered as an adjunct to L-dopa, but they are used as monotherapy as well.3  Dopamine agonists stimulate dopamine receptors on striatal neurons.3 Although dopamine agonists are reported to be effective, they have side effects too.3 There are also drugs available which limit the breakdown of dopamine.1 Monoamine oxidase type B (MAO-B) inhibitors, for example selegiline, exert their effect by restricting the degradation of dopamine and they are used to alleviate symptoms.1,7




Figure 2: Site of action of the main drug treatments for PD8

Besides drug treatment, surgical therapies are applied as well.5 At present, the primary surgical treatment employed is deep brain stimulation (DBS) of certain areas in the brain, such as the internal segment of the globus pallidus, the ventral intermediate nucleus of the thalamus or the subthalamic nucleus.5 A lead is implanted in the target area and connected to a pulse generator, which is located under the skin of the chest wall and delivers electrical stimulation to the targeted regions in the brain.5 DBS debilitates symptoms of PD, such as tremor.5 There are, however, severe risks associated with DBS.5 The surgery itself is invasive and the lead and pulse generator can cause problems like infections.5 Neuropsychiatric, cognitive and other complications have been described as well.5
The treatments mentioned above are only symptomatic therapies.1 They are unable to deal with the progressing neural degeneration.1 Moreover, these therapies often have side effects and are incapable of entirely improving later-stage symptoms.1 There is therefore a clear need for new treatments.

Since PD results from the loss of a specific cell type, namely mDA neurons, it lends itself to cell replacement therapy.9 The main goal of cell replacement therapy is to replace the degenerated and lost dopaminergic neurons, in order to restore the neuronal innervation between the substantia nigra and the striatum.9 There are different sources available for dopaminergic cell replacement therapy.9 For example, fetal ventral mesencephalic transplants.9 Freed et al. performed a double-blind, placebo controlled trial, in which PD patients received a transplant or imitation, sham surgery.10 The ventral mesencephalic tissue was obtained from 7 to 8 weeks old aborted embryos.10 The results indicated that human embryonic dopaminergic neuron transplants are able to survive in PD patients.10 Some clinical benefit was shown in younger patients, but not in older ones.10 For many reasons however, fetal tissue grafting does not seem to be the ideal replacement therapy. Only a very low percentage of the human embryonic cells survives after transplantation, approximately 10 %.2 Furthermore, the use of embryonic tissue obtained from abortions is surrounded by ethical issues and the availability of tissue is restricted.2 
The use of stem cells in cell replacement therapy seems more promising. Stem cells are generally defined by two important properties: the ability for continuous self-renewal and the capacity to differentiate into one or more specific cell types.11 In theory, stem cells can provide an unlimited supply of cells for purposes like transplantation therapies.11 Stem cells can roughly be divided in two groups; adult stem cells and embryonic stem cells.12 Adult stem cells are present in various tissues of the foetus and the organism after birth.12 These cells are multipotent, which means that they are able to differentiate into several, but not all, cell types of the body.12 Adult stem cells have an important function in the repair and replacement of tissues.12 With regard to cell replacement therapy, adult stem cells can be used to derive dopaminergic neurons.13 For instance, Lévesque et al. obtained cortical and subcortical tissue samples from the brain of a PD patient, during a neurosurgical procedure.14 The neural stem cells were isolated, expanded and differentiated in vitro.14 After nine months, a cell suspension containing differentiated dopaminergic neurons was transplanted back into the patient’s brain.14 The treatment produced a long lasting motor improvement.14 Although this approach seems to have potential, harvesting of the brain samples from the patient is very invasive and might be difficult to use in regular therapy.13 
Embryonic stem (ES) cells are intensively studied as a source for cell replacement therapy, since they exhibit numerous characteristics required for that purpose.15 
   
ES cells are derived from the inner cell 
mass (ICM) of the pre-implantation 
blastocyst (figure 3).11 This blastocyst 
consists of an outer layer of trophoblast 
cells, which form the placenta, and the ICM. Cells of the ICM will eventually give rise to the embryo and for that reason, these cells 
are capable of forming all types of tissue in the body.11 Therefore, ES cells are truly pluripotent cells and although their lifespan
in the embryo in vivo is comparatively short, they can be proliferated infinitely in vitro in an undifferentiated state.11 		
The derivation of ES cells was first	  described in 1981, from mouse species.16, 17     
ES cells provide the perfect tool for cell	   Figure 3: Derivation of ES cells18 replacement therapies for diseases like PD,		
because of their proliferative competence and the way in which their differentiation can be manipulated in vitro.9 The generation of dopaminergic neurons from ES cells is a complicated process, involving the formation of neural stem or precursor cells and ultimately the development of mature dopaminergic neurons.9 Several research groups have already established differentiated mDA neurons from mouse, primate and human ES cells, but with limited success.15 Although the generated dopaminergic neurons show morphological, functional and electrophysiological properties of mDA neurons, after transplantation into a rat model of Parkinson’s Disease, survival and phenotypic stability of the cells seems to be poor.15 Furthermore, some studies have reported tumour formation following transplantation of ES cell derived dopaminergic neurons.15 
Recently, it has been discovered that adult somatic cells can be reprogrammed to pluripotent, ES cell like cells.19 These cells are called induced pluripotent stem (iPS) cells.19 Takahashi and Yamanaka first demonstrated molecular reprogramming of mouse fibroblasts into iPS cells by introducing four genetic factors, namely Oct4, c-Myc, Sox2 and Klf4.19 In the following year, they successfully induced human pluripotent stem cells by using the same four factors.20 Like ES cells, iPS cells can be used in the development of cell replacement therapy for PD. Genetic studies have reported a linkage between several mutations in certain genes and L-dopa responsive PD.21 Many PD patients are associated with carrying of the predisposed genes.21 It would be ideal to generate iPS cells from somatic cells from a PD patient, modify the genome to correct the mutant gene, differentiate the iPS cells into dopaminergic neurons and use these for treating the same patient.21 Also, the cells of healthy individuals and PD patients, or from different developmental stages can be compared.21 This will help in elucidating the pathogenesis of PD.21 Wernig et al. have already taken some steps in the use of iPS technology for PD.22 They derived iPS cells from mouse fibroblasts, differentiated them towards a mDA neuronal fate and transplanted the differentiated cells into the striatum of rat models of PD.22 This resulted in improved behaviour of the rats.22
iPS cells could solve the problem of ethical issues surrounding the use of ES cells and immune rejection.21 However, despite the potential of iPS cells in therapies for PD, their clinical use cannot be considered yet, as there are many problems that need to be resolved.9 For instance, the efficiency of derivation of iPS cells is poor, and the iPS cell derived grafts cause a high risk of tumour formation.9

This project revolves around the use of ES cells in generating mDA neurons. The specific and efficient generation of mDA neurons from ES cells would provide knowledge that can be used in cell replacement therapies and drug discovery.

1.3 Why use rat ES cells?
The Burdon group is one of only a few in the world that are experienced in the derivation and culture of rat ES cells.23 Using rat ES cells has some advantages compared to the use of mouse, primate or human ES cells. While the use of human ES cells in cell replacement therapy shows great prospective, the fact that these cells are derived from human pre-implantation embryos makes their use highly controversial.12 The supply of human ES cells is very restricted as well.12 Non-human primate ES cells could be a proper alternative for the utilization of human ES cells, however, primates are very expensive to use and the majority of researchers do not have access to them.24 The benefits of rat ES cells in relation to mouse ES cells can partly be explained by their history as research models.25 The mouse became the research model for mammalian geneticists, because of its smaller size, which made their housing easier, and the availability of many mutants displaying Mendelian patterns of inheritance.25 The rat became the model of choice for biomedical researchers, like physiologists and nutritionists.25 The rat has been used to develop disease models and as such a rat model of PD exists.26 Generally, these Parkinsonian rats are generated by administration of the neurotoxin 6-hydroxydopamine (6-OHDA) to the rat brain.26 The specificity of 6-OHDA is due to its uptake by dopaminergic and noradrenergic transporters and it damages the neurons by oxidative stress.26 Another reason why rats are preferred above mice is that the rat, because of its larger size, provides a more practical model for experimental interventions.25

1.4 Derivation of rat ES cells
Although mouse ES cells have been consistently derived over the past three decades, the derivation of rat ES cells has remained elusive for a long time.27 In order to establish rat ES cells, researchers applied conditions developed for the culture of mouse ES cells.27 For culturing any ES cell, it must be considered that stem cells choose at each division whether to continue self-renewal or to differentiate.28 The signals that regulate this decision come from growth factors in the microenvironment of the stem cells.28 To facilitate maintenance of ES cells, long-term self-renewal must be promoted and differentiation must be suppressed.28 Mouse ES cells were originally derived and maintained by cocultivation with feeder cells, typically mitotically inactivated mouse embryo fibroblasts (MEFs), and serum.28 The main function of the fibroblast feeder cells is the secretion of the cytokine leukemia inhibitory factor (LIF).28 LIF supports self-renewal of ES cells through activation of the transcription factor STAT3.28 Serum, usually fetal calf serum, is important for the viability of undifferentiated ES cells.28 In the absence of serum, LIF is insufficient to completely inhibit differentiation and promote self-renewal.28 Serum can be replaced by bone morphogenetic proteins (BMPs).28 BMPs antagonize neural differentiation of ES cells, but promote differentiation into non-neural destinies.28 Therefore, BMPs seem unlikely to use as a factor to support self-renewal.28 However, Ying et al. showed that the combination of LIF and BMP enhances self-renewal and inhibits differentiation.28 BMPs act through binding their receptors, which main effectors are the Smad 


Figure 4: BMP/Smad pathway


transcription factors.28 Smad1, 5 and 8 are phosphorylated by the BMP receptor and then joined with Smad4. This complex translocates to the nucleus, where the transcription factors exert their function.28 Important targets of BMP/Smad signalling are the Inhibitor of differentiation (Id) genes (figure 4).28 Id proteins are factors that repress gene transcription required for differentiation and promote cell growth.28 Id genes are induced by serum as well.28
The combination of LIF, to activate STAT3, and either serum or BMP, to stimulate Id proteins is commonly used for the maintenance of mouse ES cells.27 Rat ES cells, adversely, have never been established using similar culture conditions.27 A few years ago, Ying et al. found that maintaining self-renewal of mouse ES cells does not necessitate activating signals from LIF/STAT3 and BMP/Smad signalling, 
but only that the exposure of ES cells to inductive differentiation stimuli must be
prevented.29 Differentiation of ES cells involves fibroblast growth factor-4 (FGF4), which is produced by undifferentiated ES cells in an autocrine way.29, 30 FGF4 stimulates the mitogen-activated protein
kinase (MAPK) pathway (figure 5).29 
MAPK is often confused with extracellular regulated kinase (ERK), but ERK is in fact the name for one specific group of isoforms    Figure 5: FGF stimulation of the
within the MAPK family and one of the          MAPK pathway31
important molecules in the MAPK 
signalling cascade.32 Mitogen-activated ERK-activating kinase (MEK) is another important factor in this cascade and functions as an upstream molecule of ERK.32 Stimulation of the cascade by FGF4 forces ES cells to stop self-renewal and induces differentiation.30 Therefore, Ying et al. used selective small-molecule inhibitors to inhibit the MAPK pathway and thus inhibit differentiation.29 The inhibitor SU5402 was used to inhibit FGF receptor tyrosine kinases and the inhibitor PD184352 was applied to inhibit the ERK cascade.29 By application of low doses of SU5402 and PD184352 together, undifferentiated ES cells expanded and differentiation was restricted.29 Nevertheless, a high level of cell death was observed and the viability of the cells seemed to be compromised.29 For that reason, a third inhibitor was added.29 
CHIR99021 is a selective inhibitor of glycogen synthase kinase-3 (GSK3).29 GSK3 mediates negative regulation of biosynthetic pathways.29 Inhibition of GSK3 might reinstate ES cell growth to cells cultured with SU5402 and PD184352.29 CHIR99021 on its own improves cell survival, but induces non-neural differentiation as well.29 In the combination of all three inhibitors, also referred to as 3i, the inhibiting effect of SU5402 and PD184352 on differentiation is superior and undifferentiated ES cells can be proliferated efficiently.29 An overview of the effects of LIF/BMP and 3i on ES cell self-renewal is given in figure 6.













Figure 6: Schematic representation of maintenance of self-renewal by either LIF/BMP or 3i. 


In order to avert the unwanted side effects of inhibiting the FGF receptor, SU5402 was excluded and PD184352 was replaced by the more potent MEK inhibitor PD0325901.23, 27 It was found that PD0325901 combined with the GSK3 inhibitor CHIR99021, also referred to as 2i, is sufficient to derive and maintain rat ES 
cells.23, 27 At present, the Burdon lab has actually derived rat ES cells using only one inhibitor, namely PD0325901.(Unpublished data) 

1.5 Midbrain development in vivo
To facilitate the differentiation of ES cells into mDA neurons in vitro, it is important to understand the mechanisms of mDA neuron differentiation in vivo. 
In the mature brain, mDA neurons are separated into different subgroups based on their location in the midbrain and the structures that they innervate.33 There are the neurons of the substantia nigra compacta (SNc) and the neurons of the ventral tegmental area (VTA).33 The VTA neurons project to the ventromedial striatum, cortical areas and the limbic system.33 These neurons are involved in emotional behaviour and mechanisms of reward and defects of the VTA neuron system lead to psychiatric disorders.33 The dopaminergic neurons of the SNc mainly project into the dorsolateral striatum and are responsible for motor function.33 PD arises as a result of the degeneration of SNc neurons.33 
Differentiation of SNc neurons in vivo consists of 3 important processes: regionalisation of the neural plate, determination of midbrain cell fate and terminal differentiation into mDA neurons.33 

Regionalisation of the neural plate
In an early stage of embryonic development, the lateral edges of the neural plate roll up and form a tube.33 At the anterior side of the tube a constriction develops, known as the midbrain hindbrain border (MHB) or isthmus.33, 34 The MHB forms the boundary between the future midbrain and hindbrain.33 Together with signals from the mesoderm and endogenous genes that regulate regional patterning, the MHB specifies certain areas of neural tissue in the developing midbrain and hindbrain.33 There are two main signals required for the induction of dopaminergic neurons.34 Fibroblast growth factor 8 (Fgf8) is expressed in the MHB.34 Fgf8 induces anterior-posterior identity of the midbrain and plays a role in defining midbrain cell fate.33, 34 Sonic hedgehog (Shh) is expressed by the notochord and is secreted by cells of the floor plate, located in the ventricular neuroepithelium of the ventral midbrain.33, 34 Shh is important for dorsal-ventral patterning of the midbrain.33, 34 Ventral cells of the midbrain acquire a dopaminergic cell fate in response to Shh expression.33 The intersection of the concentration gradients of Fgf8 and Shh regulates the development of dopaminergic neurons (figure 7).34
Figure 7: The birth of DA neurons is regulated by the intersection of the
concentration gradients of Fgf8 and Shh.34

The MHB is positioned between the expression domains of the transcription factors Otx2 and Gbx2.35 Gbx2 is expressed caudally from the MHB and suppresses midbrain development, whereas Otx2 is expressed on the rostral side of the MHB and suppresses development of hindbrain.35 Otx2 is a homeodomain transcription factor which, besides its function in restricting hindbrain development, is also required for restraining the level of dorsal Shh expression in the ventral midbrain and positioning Wnt1 and Fgf8 expression in the MHB.36 Wnt1 is a secreted molecule, involved in ventral midbrain proliferation and instructing differentiation of dopaminergic neurons.34 It is expressed in the MHB, but primarily on the side of the midbrain.35 Wnt1, and Fgf8 as well, are shown to be induced by Lmx1b.37, 38
Lmx1b, a LIM homeodomain transcription factor, is at first expressed throughout the ventral mes- and diencephalon, but becomes limited to post-mitotic mDA neurons later in development.35 Lmx1b is crucial for the induction and maintenance of the activity of the MHB.38 Around this stage, the Engrailed homeodomain transcription factors En1 and En2 are also expressed.35 In the developing brain, En1 and En2 are expressed on both sides of the MHB.35 In the adult midbrain, En1 is expressed at high levels in the SNc and VTA, while the expression level of En2 is lower and limited to a subset of the cells expressing En1.35 En1 and En2 are required for the survival of mDA neurons.35

Determination of midbrain cell fate
At this stage, the neuroepithelium of the midbrain develops and becomes thicker by cell proliferation.33 Distinct layers can be distinguished at this point.33 The cells located in a band near the ventricle maintain their properties as proliferative stem cells.33 Other cells depart this proliferative zone, exit the cell cycle and start differentiating.33 The mDA neuron progenitors occupy the proliferative zone on the ventral most side.33 From there, they initially move in a ventral direction followed by a lateral movement, while they differentiate.33 These cells express Lmx1b, Lmx1a, Foxa2, Msx1, Msx2, Ngn2 and, at an early stage, Shh.33 When cells reach this stage, they obtain mDA neuronal specification and enter the last steps of differentiation.33 
Shh induces Lmx1a expression.33 Like Lmx1b, Lmx1a is a member of the family of LIM homeodomain transcription factors.36 Lmx1a expression starts in the ventral midbrain and then expands progressively towards dorsal.36 Shh and Lmx1a are both essential and adequate to induce mDA neurons.33 Unlike Shh, Lmx1a is expressed continually during the production of mDA neuron progenitors.33 Shh is able to regulate the expression of Foxa2 as well.33 Foxa2 is a forkhead/winged helix transcription factor.39 Foxa2 positively regulates the expression of Ngn2 and is also involved in regulating Nurr1 and En1 expression in immature mDA neurons and TH expression in mature mDA neurons.39 Ngn2 is a proneural basic helix-loop-helix gene, which is expressed in mDA progenitors, the more dorsally located ventricular zone and newborn postmitotic immature mDA neurons directly flanking the ventricular zone.36 Ngn2 mediates the shift of a cell from the proliferative zone to the intermediate zone, which is situated ventrally from the proliferative zone.33 It is also needed for the generation of immature, Nurr1 expressing mDA neurons.36 Msx1, a homeodomain transcription factor, is expressed in the proliferative zone as well.33, 36 Msx1 acts synergistically with Lmx1a to promote the population of mDA neuron progenitors.33 The cooperation of Msx1 and Lmx1a results in the upregulation of Ngn2.33  


Terminal differentiation into mDA neurons
Cells in the intermediate zone begin to express Nurr1 and Pitx3.33 When they migrate further and reach the ventral peripheral edge of the neuroepithelium, they are completely differentiated mDA neurons.33 The last step in dopaminergic neuron differentiation is the expression of tyrosine hydroxylase (TH).33, 36 TH is the first and also rate-limiting enzyme in the biosynthesis of dopamine.33, 36 Nurr1 is a transcription factor belonging to the family of orphan nuclear receptors.36 It regulates TH expression, after it is phosphorylated by ERK, and is important for the survival of mature dopaminergic neurons as well.33, 36 TH is also regulated by Pitx3, a paired-like homeodomain protein expressed in both SNc and VTA dopaminergic neurons.33 Pitx3 is positively controlled by Lmx1b and Wnt1.33
Lmx1b plays a role in maintaining TH expressing mDA neurons.36 Maintenance of the mDA neurons late in embryonic development and in adulthood requires expression of En1 and En2.33 
An outline of the expression of the key players in mDA neuron development is illustrated in figure 8. The timing of expression of some factors in mouse embryo’s is shown in figure 9. 





Figure 8: Schematic illustration of the main factors of mDA neuron development.33


Figure 9: The timing of transcription factor expression in mDA progenitors. Dotted lines point out that the exact timing of shutdown of expression has not been determined.36


1.6 Neural differentiation in vitro
The generation of mDA neurons from ES cells in vitro involves directing ES cell differentiation into a neuronal cell fate.33 Kawasaki et al. showed that dopaminergic neurons can be efficiently induced by culturing ES cells on a layer of bone marrow derived PA6 stromal cells.40 PA6 cells produce stromal cell-derived inducing activity (SDIA), which promotes neural differentiation of cocultured ES cells.40
Because ES cell differentiation in vitro largely mimics development in vivo, it is also possible to apply known extracellular factors during ES cell differentiation and thereby induce a transcription cascade comparable to normal development.33 
Lee et al. used a five step protocol to obtain neurons.41 The first step consisted of expanding the undifferentiated ES cells in the presence of LIF.41 During the second step, embryoid bodies (EBs) were generated.41 EBs are ES cell aggregates, which form when ES cells are cultured in suspension in the absence of LIF.41, 42 They show many aspects of cell differentiation in early embryonic development and are able to constitute cells of all three germ layers.42 The third step was to select for stem cells of the central nervous system (CNS) from the EBs.41 In the fourth step, the CNS stem cells were proliferated in the presence of basic fibroblast growth factor (bFGF).41 Finally, differentiation of the expanded neuronal precursor cells was induced by removing bFGF.41 The differentiation of ES cells into mDA neurons in vitro, should be reliant on the stimulation of the same genes expressed in CNS stem cells and neurons in vivo, as has been described above.41 Therefore, using the expression of these genes as a marker helps to identify the nature of the generated neurons.41 Demonstration of TH expression, would indicate terminal differentiated dopaminergic neurons.41 It has been shown that application of Shh, Fgf8 and ascorbic acid (AA) increased the yield of ES cell derived TH expressing neurons.41  
Ying et al. reported that neither coculture nor cellular aggregation is needed to direct ES cells to a neural fate.43 They showed that ES cells can be converted into neuroectodermal precursors in adherent monoculture.43 It has been demonstrated that ES cells develop into neural precursors, in the absence of serum or supplemented growth factors.43 This process is not a default pathway, as it requires autocrine FGF.43 Ying et al. induced differentiation in the absence of serum, by withdrawal of LIF.43
The experiments mentioned previously were all conducted on mouse ES cells. Chang et al. used iPS cells derived from rats to generate dopaminergic neurons in vitro.44 The potential of the rat iPS cells to differentiate into neural cell types, including dopaminergic neurons, was examined based on the five step protocol from Lee et al.41, 44 It was shown that the rat iPS cells were able to differentiate into all neural lineage phenotypes.44 The appliance of Shh, Fgf8 and AA resulted in a high yield of dopaminergic neurons (9.2±3.7% of total amount of neurons).44
Researchers of the Burdon team found that neural differentiation of rat ES cells can be established by adjusting the level of MEK/ERK inhibition.(Unpublished data) Rat ES cells were cultured in the presence of CHIR99021 and different concentrations of PD0325901. Figure 10 shows the results of a semi-quantitative RT-PCR analysis of the expression of certain genes at the different inhibitor conditions. No reverse transcriptase (RT), serves as a negative control. βactin, a gene expressed in all nucleated cell types, was used as a loading control.45 At lower concentrations expression of the ESC marker Oct4 is reduced, indicating a loss of pluripotency.46 Conversely, markers of the neural lineage Nestin and Pax6 were both increased. Nestin is expressed in neuroepithelial stem cells and muscle precursors.47 Pax6 is a marker commonly found in neural tissue.48 Interestingly, when cells were cultured in the absence of PD0325901, no Pax6 expression was observed (a condition in which neural differentiation is expected to be favoured). Rather, there was an increase in muscle markers myogenin and Myf5 in this condition. These results suggest that neural differentiation is enhanced by using low concentrations of PD0325901, but without the presence of PD0325901 muscle differentiation is promoted, probably due to the effects of CHIR99021.(Unpublished data) These results are supported by an immunohistochemistry analysis of the cells at a concentration of 0.25μM PD0325901 (figure 11). The green staining indicates the expression of β-ІІІ tubulin, a neuronal marker.41 The red staining shows Nestin expression and the blue color DAPI, which stains DNA.49 Figure 11 shows a high amount of β-ІІІ tubulin in a typical morphology, indicating neural differentiation.(Unpublished data) 

Figure 10: RT-PCR analysis of 		Figure 11: Immunohistochemistry PD0325901 titration samples for Oct4,	analysis of differentiated rat ES cells
Nestin, Pax6, Myogenin, Myf5, βactin and	cultured in the presence of 0.25μM
a sample without reverse transcriptase. 	PD0325901; red stain: nestin, green
stain: β-ІІІ tubulin, blue stain: DAPI . 


Figure 12: Immunohistochemistry analysis of rat ES cells cultured without the presence of PD0325901; green stain: myosin, blue stain: DAPI.

Moreover, an immunohistechemistry analysis of the rat ES cells cultured in the absence of PD0325901 was performed as well. Figure 12 clearly shows the presence of myosin (green stain), which indicates muscle differentiation. 

1.7 This project
This project continues the work of the Burdon team on neural differentiation of rat ES cells. The specific and efficient differentiation of rat ES cells into mDA neurons would provide a tool for modelling cell replacement therapy in PD rat models and facilitate drug discovery. To assess the degree of mDA differentiation present in the PD0325901 titration samples, RT-PCR conditions for markers of midbrain specification and mature mDA neurons will be optimized and the PD0325901 titration samples will be evaluated for midbrain marker expression by RT-PCR analysis. 

Hypothesis:
















2 ml B27 no Vit.A	Gibco	12587-010
2 ml L-glutamine	Roslin stores	

N2B27 medium containing 2i or 1i:
2i Media	1i Media
10ml  N2B27	10ml  N2B27
10µl  1mM PD0325901 (MEK inhibitor)	10µl  1mM PD0325901 (MEK inhibitor)
30µl  1mM CHIR99021 (GSK3 inhibitor)	
100µl  Pen/Strep (Roslin stores, 100x)	100µl  Pen/Strep (Roslin stores, 100x)
N.B.: PD0325901 and CHIR99021 are obtained from University of Dundee
2.2 Experimental outline
The main goal of this project was to examine PD0325901 titration samples, which were established by Stephen Meek, for the presence of mDA neuronal markers. The samples were derived from rat ES cells from a Fisher 4.4 line, cultured on laminin coated wells for 11-14 days in the presence of 1.5μM CHIR99021 and 7 different concentrations of PD0325901 (2.0μM, 1.5μM, 1.0μM, 0.75μM, 0.5μM, 0.25μM and 0μM). Before RT-PCR analysis of the PD0325901 titration samples was performed, RNA and cDNA were purified and the RT-PCR conditions for the mDA neuronal markers were optimized. Meanwhile, rat ES cells were cultured and neural differentiation experiments were set up.
2.3 RNA and cDNA purification
RNA and cDNA were purified for RT-PCR analysis.
2.3.1 Purification of total RNA from rat brain
RNA purification was performed using the RNeasy® Mini Kit (Qiagen), following the protocol for ‘purification of total RNA from animal tissues’ in the RNeasy® Mini Handbook (Fourth edition, april 2006, Qiagen) as described below: 
-Remove the brain sample from storage (or excise the sample from the animal)
-Weigh the brain sample and add 30mg to a 7ml bijous
-Add ß-Mercaptoethanol (ß-ME) to Buffer RLT in a fume hood. Add 10µl ß-ME per 1ml Buffer RLT.
-Add 600µl Buffer RLT (+ß-ME) to the 30mg brain sample
-Disrupt and homogenize the sample using a rotor-stator homogenizer. Clean the rotor-stator homogenizer before use with 4M sodiumhydroxide and water.
-Pipet 600µl of the sample into a QIAshredder spin column placed in a 2ml collection tube and centrifuge for 2 min. at full speed
-Remove the supernatant by pipetting and transfer it to a new 2ml collection tube
-Add 1 volume of 70% ethanol and mix by pipetting
-Transfer 700µl of the sample to an RNeasy spin column placed in a 2ml collection tube and centrifuge for 15sec. at 10000rpm
-Discard the flow-through
-Transfer the remaining sample to the spin column and centrifuge again for 15 sec. at 10000rpm
-Discard the flow-through
-Add 350µl Buffer RW1 to the spin column and centrifuge for 15 sec. at 10000rpm
-Discard the flow-through
-Add 10µl DNase 1 stock solution to 70µl Buffer RDD and mix by pipetting
-Add 80µl of the DNase 1 incubation mix directly to the spin column membrane and incubate for ± 30 min.
-Add 350µl Buffer RW1 to the spin column and centrifuge for 15 sec. at 10000rpm
-Discard the flow-through
-Add 4 volumes of ethanol (96-100%) to Buffer RPE
-Add 500µl Buffer RPE to the spin column and centrifuge for 2 min. at 10000rpm
-Place the spin column in a new 2 ml collection tube and centrifuge for 1 min. at full speed
-Place the spin column in an Eppendorf tube
-Add 35µl RNase free water and centrifuge for 1 min. at 10000rpm

2.3.2 Purification of total RNA from rat ES cells
RNA purification was performed using the RNeasy® Mini Kit (Qiagen), following the protocol for ‘purification of total RNA from animal cells using spin technology’ in the RNeasy® Mini Handbook (Fourth edition, april 2006, Qiagen) as described below:
-Pellet the cells: 	-Aspirate media off from well
			-Add 200µl CDB to the well
			-Aspirate the CDB off
			-Add 200µl CDB to the well 
			-Incubate for ± 5 min. at 37°C
			-Dissociate the cells by pipetting
			-Transfer the content of  the well to an Eppendorf tube
			-Add 1ml PBS to the Eppendorf tube
			-Centrifuge for 3 min. at 10000rpm
			-Aspirate the PBS off (leave a little bit at the bottom)
-Loosen the cell pellet by flicking the tube
-Add ß-Mercaptoethanol (ß-ME) to Buffer RLT in a fume hood. Add 10µl ß-ME per 1ml Buffer RLT.
-Add 350µl Buffer RLT to the cells and mix by pipetting
-Pipet the lysate directly into a Qiashredder spin column placed in a 2ml collection tube and centrifuge for 2 min. at full speed
-Add 1 volume of 70% ethanol to the homogenized lysate and mix by pipetting
-Transfer 700µl of the sample to an RNeasy spin column placed in a 2ml collection tube and centrifuge for 15sec. at 10000rpm
-Discard the flow-through
-Transfer the remaining sample to the spin column and centrifuge again for 15 sec. at 10000rpm
-Discard the flow-through
-Add 350µl Buffer RW1 to the spin column and centrifuge for 15 sec. at 10000rpm
-Discard the flow-through
-Add 10µl DNase 1 stock solution to 70µl Buffer RDD and mix by pipetting
-Add 80µl of the DNase 1 incubation mix directly to the spin column membrane and incubate for ± 30 min.
-Add 350µl Buffer RW1 to the spin column and centrifuge for 15 sec. at 10000rpm
-Discard the flow-through
-Add 700µl Buffer RW1 to the spin column and centrifuge for 15 sec. at 10000rpm
-Discard the flow-through
-Add 4 volumes of ethanol (96-100%) to Buffer RPE
-Add 500µl Buffer RPE to the spin column and centrifuge for 15 sec. at 10000rpm
-Discard the flow-through
-Add 500µl Buffer RPE to the spin column and centrifuge for 2 min. at 10000rpm
-Place the spin column in a new 2ml collection tube and centrifuge for 1 min. at full speed
-Place the spin column in an Eppendorf tube 
-Add 35µl RNase free water and centrifuge for 1 min. at 10000rpm
-Store at -80°C

2.3.3 cDNA synthesis from purified total RNA
cDNA synthesis was performed using SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen), following the protocol ‘First-Strand synthesis using oligo(dT)’ from the included guide (March 2007, Invitrogen) as described below:
-Add 8µl RNA to an Eppendorf tube
-Add 1µl 10mM dNTP mix to the Eppendorf tube
-Add 1µl 0.5 µg/µl oligo(dT) to the Eppendorf tube
-Incubate the RNA/primer mixture for 5 min. at 65°C, then place on ice for 1 min. and centrifuge briefly to get rid of the condensation
-Prepare the following reaction mix in a separate tube:
	For 1 reaction:
	-2µl 10x RT buffer
	-4µl 25 mM MgCl2
	-2µl 0.1 M DTT
	-1µl RNaseOUT™ (40 U/µl)
-Add 9µl reaction mix to the RNA/primer mixture, mix by pipetting and collect by brief centrifugation
-Incubate for 2 min. at 42°C
-Add 1µl of SuperScript™ ІІ RT to the tube
In the case of a minus RT control: Add 1µl DEPC-treated water instead of RT
-Incubate for 50 min. at 42°C 
-Incubate for 15 min. at 70°C, then place on ice 
-Centrifuge briefly and add 1µl RNase H to the tube
-Incubate for 20 min. at 37°C
-Store at -20°C
After the cDNA sythesis was completed, the concentration of the cDNA was measured with a spectrophotometer (NanoDrop). The cDNA samples were diluted with water to a concentration of 200ng/µl.
2.4 RT-PCR
The primers used for this project are listed in Appendix 1, along with the primer sequences, size, percentage of G and C oligonucleotides, melting temperature and the product size. Primers were designed by Stephen Meek.





-0.2µM forward primer 
-0.2µM reverse primer 
-200ng/µl cDNA
-5 units/µl Taq polymerase
RT-PCR amplifications were run in a DNA Engine Dyad Peltier thermal cycler. The reaction mixture was exposed to a temperature of 94ºC for 2 min., followed by amplification during 30 or 32 cycles (each cycle consisted of denaturation at 94ºC for 30 sec., annealing at a temperature ranging from 50ºC to 63 ºC for 40 sec. and elongation at 72ºC for 40 sec.) and final extension at 72ºC for 10 min. The specific RT-PCR conditions for each primer pair are included in Appendix 2.
The presence of amplified products was detected by gel electrophoresis, using a 2% agarose gel (1g. agarose in 50ml TBE Buffer) on 50V. 12µl 5x TBE loading buffer (40% sucrose, x5 TBE Buffer, ddH2O, bromophenol blue) was added to each 50µl reaction mixture, before loading the gel. 15µl of each sample was loaded on the gel. In order to be able to estimate the size of the amplified products, 5µl 1Kb DNA ladder (TrackIt, Invitrogen, Cat. no. 10488-085) was loaded in adjacent lanes. Gels were stained for ± 15min. in an ethidium bromide bath. An image of the gel was taken utilizing UV-light (Kodak Gel Logic 200 Imaging System). 
2.5 Rat ES cell lines
For this project, four different rat ES cell lines were used:
-Roslin Institute Dark Agouti (RIDA) 27
-Roslin Institute Brown Norway (RIBN) 1
-Roslin Institute Fisher (RIF) 4.1
-Roslin Institute Dark Agouti (RIDA) 6.8
The  and  cell lines were used during the first part of the project, whereas the two RIRIF4.1 and RIDA6.8 cell lines were used through the last part.
2.5.1 Culture of rat ES cells
RIDA27 and RIBN1 cell lines were cultured in 4-well plates on DIA-M (Differentiation Inhibiting Activity-Matrix bound) feeders, which are mouse fibroblasts that express LIF. The RIDA27 cell line was cultured in 1i medium and the RIBN1 cell line was cultured in 2i medium. 
Every 1-2 days a half media change was performed. Media was partly aspirated from the wells, whereupon fresh media was added. RIDA27 and RIBN1 cell lines were passaged according to their confluence, with an average of every 3-4 days. A cell passage was performed as follows:
-Aspirate medium off from the well 
-Add 200µl Cell Dissociation Buffer (CDB) to the well
-Aspirate the CDB off 
-Add 200µl CDB to the well
-Incubate the well at 37°C for ± 5 min.
-Dissociate the cells by pipetting
-Transfer the content of the well into a 15ml tube containing 5ml N2B27
-Centrifuge the tube for 3 min. at 1000 rcf
-Aspirate N2B27 off from the tube and resuspend the pellet in 200µl N2B27 + 1i/2i
-Count the cells with the use of a haemocytometer
-Plate the cells in the desired density on DIA-M feeders in 500µl N2B27 + 1i/2i
-Incubate the cells at 37°C

The RIF4.1 and RIDA6.8 cell lines were cultured feeder-free and were plated on laminin. The cell lines were derived in 2i medium.

2.6 Neural differentiation 
Neural differentiation was performed using the following protocols.

Laminin coating of wells:
Laminin is stored at a concentration of 1mg/ml. 
-Dilute laminin 1:50 in phosphate buffered saline (PBS) to 20µg/ml
-Add 500µl 20µg/ml laminin to each well 
-Incubate the wells for at least 2 hours
-Wash the wells 3x with 500µl PBS before use

Gelatin coating of wells:
-Add 500µl gelatin to each well
-Aspirate gelatine off after a few minutes

Setting up neural differentiation:
-Aspirate media off from wells
-Add 200µl CDB to the wells
-Aspirate the CDB off 
-Add 200µl CDB to the wells 
-Incubate the well at 37°C for ± 5 min.
-Dissociate the cells by pipetting
-Transfer the content of the well into a 15ml tube containing 5ml N2B27
-Centrifuge the tube for 3 min. at 1000 rcf
-Aspirate N2B27 off from the tube and resuspend the pellet in the desired amount of N2B27
-Add 1ml of the content of the tube to each gelatin coated well
-Incubate the wells at 37°C for 10-15 min.
-Transfer the upper part of the content of the wells to a 15ml tube containing 5ml N2B27
-Centrifuge the tube for 3 min. at 1000 rcf
-Aspirate N2B27 off from the tube and resuspend the pellet in 200µl N2B27
-Count the cells with the use of a haemocytometer
-Plate the cells in the desired density on laminin coated wells in 500µl of the desired medium
-Incubate the wells at 37°C 
2.7 Immunohistochemistry
Undifferentiated rat ES cells were fixed and immuno-stained for the pluripotency markers Oct4 and Nanog. The cells were stained for the DNA-marker DAPI as well. Staining and fixation of the cells was carried out according to the protocol described below.
Antibodies used:
Primary antibodies:
Oct4 antibody – Santa Cruz (C10) mouse monoclonal IgG2b.
Nanog antibody – Abcam ab80892 rabbit polyclonal IgG.
Secondary antibodies:
Secondary for Oct4 – Goat anti-mouse IgG2b Alexa 488
Secondary for Nanog – Goat anti-rabbit IgG Alexa 568.

Fixation of cells:
-Wash the well with 500µl PBS
-Fix in 500µl 4% paraformaldehyde (PFA) for 15 minutes at room temperature.
-Wash the well twice with 500µl PBS.
-If storing, leave the second PBS wash on the cells, wrap the plate with parafilm and store at 4oC.

Staining of cells:
-Wash the fixed well 4 x 10 minutes with 500µl PBST (PBS + 0.3% TritonX100)
-Make blocking solution (PBST + 1% BSA + 10% serum – serum from same species as secondary antibody was raised in)
-Add 500µl blocking solution to the well and block for 1 hour at room temperature
-Dilute primary antibodies 1:200 in blocking solution 
-Aspirate the blocking solution of from the well
-Add 500µl primary antibody solution to the well 
-Wrap the plate with parafilm and leave the plate overnight at 4oC
-Wash the well 4 x 10 minutes with 500µl PBST
-Dilute secondary antibodies 1:1000 in blocking solution
-Add 500µl secondary antibody solution to the well
-Incubate 1 hour at room temperature in the dark
-Wash the well 3 x 10 minutes with 500µl PBST
-Dilute DAPI 1:10000 in PBST
-Add 500µl DAPI solution to the well and incubate 5 minutes at room temperature
-Wash the well twice with PBS and leave the second wash on the cells
-Take images and/or wrap the plate in parafilm and foil and store at 4oC 









3.1 Optimization of RT-PCR conditions for primers of mDA neuronal markers

3.1.1 RT-PCR analysis of adult rat brain and day 10.5 rat embryo cDNA samples for several markers of midbrain specification
RT-PCR was performed on adult rat brain and day 10.5 rat embryo (rE10.5) cDNA samples, for several markers of midbrain specification, using ‘standard’ RT-PCR conditions (ddH2O, x1 Buffer, 1.5mM MgCl2, 0.4mM dNTPs, 0.2µM forward primer, 0.2µM reverse primer, 200ng/µl cDNA, 5 units/µl Taq polymerase). ßactin2 served as a loading control. The results are displayed in figure 13. Under these conditions, PCR products of the expected size were obtained for En2, Foxa2 and Nurr1. However, no  PCR products were observed for Lmxb1, Otx2 or Msx1. Therefore, PCR conditions were further optimised for these markers.


Figure 13: RT-PCR of adult rat brain and day 10.5 rat embryo 
for mDA neuronal markers; (1) ddH2O, (2) adult rat brain, 
no reverse transcriptase, (3) adult rat brain, + reverse transcriptase, 
(4) day 10.5 rat embryo, no reverse transcriptase, 
(5) day 10.5 rat embryo, +reverse transcriptase 

3.1.2 Optimization of RT-PCR conditions
Optimization of RT-PCR conditions for the primer pairs of mDA neuronal markers, consisted of one or more of the following points:
-Optimize primer concentration: A primer concentration that is too high, might result in the creation of primer-dimers and non-specific PCR products. However, if the primer concentration is too low, the yield of product might be too low to detect. In order to find the optimal primer concentration for a specific primer pair, four different primer concentrations (0,1 µM; 0,2 µM; 0,4 µM and 0,8 µM) were applied.
-Optimize MgCl2 concentration: Magnesium functions as a necessary co-factor for thermostable DNA polymerases. If the MgCl2 concentration is too low, the yield of PCR product will be low. Excess magnesium increases the yield of non-specific PCR products. Therefore, four different MgCl2 concentrations (1,0 mM; 1,5 mM; 2,0 mM and 2,5 mM) were used to find the optimum concentration for a specific primer pair.
-Optimize annealing temperature: When the annealing temperature is too high little or no product will be obtained due to reduced primer binding. Similarly, if the annealing temperature is too low, non-specific PCR products will be formed and the yield of product will decrease. To facilitate a higher yield of PCR product and to diminish the formation of non-specific products, an annealing temperature gradient was applied to find the most favourable annealing temperature.










Figure 14: Optimization of RT-PCR conditions for the primer pairs of Msx1, Otx2, Lmx1b, TH and Pitx3, a red square indicates the determined ‘optimal’ conditions; (1) ddH2O, (2) adult rat brain, no reverse transcriptase, (3) adult rat brain, + reverse transcriptase, (4) day 10.5 rat embryo, no reverse transcriptase, (5) day 10.5 rat embryo, +reverse transcriptase
3.2 RT-PCR analysis of PD0325901 titration samples
Prior to this project, the Burdon team found that neural differentiation of rat ES cells can be induced by adjusting the level of MEK/ERK inhibition. Rat ES cells were exposed to 1.5 µM CHIR99021, which is half the concentration used in 2i media, and several concentrations of PD0325901 (2,0 µM; 1,5 µM; 1,0 µM; 0,75 µM; 0,5 µM; 0,25 µM and 0 µM) were applied. RNA and cDNA samples were prepared from these cells. 
Samples were evaluated for midbrain marker expression by RT-PCR analysis, to determine whether there is evidence of mDA neurons present in the samples. RT-PCR analysis was performed twice, with different cDNA samples.
The PD0325901 titration samples were derived from a Fisher 4.4 rat ES cell line. Therefore, undifferentiated Fisher ES cells on DIA-M feeders were used as a control. DIA-M feeders were used as a control to determine whether any expression in the sample containing undifferentiated ES cells was due to the ES cells or to the feeder cells present in that sample. ddH2O was used as a negative control. r.E10.5 and adult rat brain were used as positive controls. To rule out amplification from potential genomic DNA contamination, primers were designed to span introns, and a no RT control was also performed as a negative control. The first RT-PCR analysis was carried out for the midbrain markers Otx2, En2, Foxa2, Nurr1, the pan neuronal marker Pax6 and for βactin2, which served as a positive control. The results are displayed in figure 15. Five PD0325901 titration samples were used for this analysis, namely the samples that were exposed to a PD0325901 concentration of 2,0 µM, 1,5 µM, 1,0 µM, 0,5 µM or 0 µM. The negative controls that were synthesized without RT were negative (not shown in the figure).

Figure 15: First RT-PCR analysis of  PD0325901 titration samples for some midbrain neuronal markers; (1) ddH2O, (2) DIA-M feeders, (3) day 10.5 rat embryo, (4) adult rat brain, (5) Fisher 4.6 ES cells on DIA-M feeders, (6) Fisher 4.4, 2,0 µM PD0325901, (7) Fisher 4.4, 1,5 µM PD0325901, (8) Fisher 4.4, 1,0 µM PD0325901, (9) Fisher 4.4, 0,5 µM PD0325901, (10) Fisher 4.4, 0 µM PD0325901

The second and final RT-PCR analysis was executed on a different batch of cDNA samples. Again, five PD0325901 titration samples were analysed, but compared to the previous RT-PCR analysis, with a slight difference in the PD0325901 titration samples that were used. This time, the analysis was performed on the samples that were exposed to a PD0325901 concentration of 2,0 µM, 1,0 µM, 0,5 µM, 0,25 µM, or 0 µM. The PD0325901 titration samples were analysed for the midbrain markers Otx2, Lmx1b, En2, Msx1, Foxa2, Nurr1, Pitx3 and TH, the pan-neuronal marker Pax6, the pluripotency markers Oct4, Nanog, Rex1 and Klf4, and for βactin2. The results are demonstrated in figure 16. The negative controls that were synthesized without RT were negative (not shown in the figure).


Figure 16:Second RT-PCR analysis of  PD0325901 titration samples for midbrain neuronal markers; (1) ddH2O, (2) DIA-M feeders, (3) day 10.5 rat embryo, (4) adult rat brain, (5) Fisher 4.4 ES cells on DIA-M feeders, (6) Fisher 4.4, 2,0 µM PD0325901, (7) Fisher 4.4, 1,0 µM PD0325901, (8) Fisher 4.4 0,5 µM PD0325901, (9) Fisher 4.4, 0,25 µM PD0325901, (10) Fisher 4.4, 0 µM PD0325901
3.3 Neural differentiation
Besides the RT-PCR analysis of PD0325901 titration samples for midbrain markers, an attempt was made to differentiate rat ES cells into a neuronal and possibly even to a mDA neuronal fate. 

3.3.1 The undifferentiated rat ES cells






















Figure 17: Bright field microscopic picture of rat ES cell colonies (x100)





Figure 18: Immunohistochemistry of RIDA27, RIBN1, RIF4.1 and RIDA6.8 cell lines for Oct4 (green stain) and Nanog (red stain), in combination with DAPI staining (blue stain).

3.3.2 Neural differentiation using RIDA27 and RIBN1
The first neural differentiation experiment was set up, using RIDA27 and RIBN1 cell lines. The cells were plated on laminin coated wells (20µg/ml) of a 24-well plate. Each cell line was plated in four different densities (5x103 cells/well, 1x104 cells/well, 2x104 cells/well and 3x104 cells/well) to determine the optimal density for neural differentiation. RIDA27 was plated in N2B27 + 1i and RIBN1 was plated in N2B27 + 2i. 
One day after plating, 500µl N2B27 was added to each of the 8 wells. Four days after plating, a complete media change was performed. Media was removed and the cells were washed with 500µl PBS, then 1ml N2B27 was added to each well.
During the experiment, bright-field pictures of the cells were taken every 1-2 days (not shown). One day after plating, the cells seemed to have plated down well. However, during the following days the cells started to die. Three days after plating, all cells from both cell lines plated at a density of 5x103 cells/well and 1x104 cells/well had died. Five days after plating, the cells at the higher densities had also died.

3.3.3 Neural differentiation using RIDA27
For the second neural differentiation experiment, RIDA27 cell line was used. Because of the cell death in the previous experiment, this experiment focused on enhancing cell survival en finding the optimal conditions for neural differentiation. Neural differentiation was set up, but instead of using CDB to dissociate the cells, trypsin (TVP) was applied. 200µl TVP was added to the wells, the wells were incubated at 37°C for ± 2 min. and the cells were spun down in GMEM (Glasgow Minimal Essential Medium). After counting, the cells were plated in a density of 1x104 cells/well on laminin coated wells (2cm2) in three different media:
-Well 1: N2B27
-Well 2: N2B27 + 2i
-Well 3: N2B27 + 1.5µM CHIR99021 and 0.25µM PD0325901 (N2CHPD)
These three media were applied to examine cell survival and possibly neural differentiation in the different media. N2B27 + 2i was used, because the cells are comfortable in this medium and the inhibitors enhance cell survival. However, inducing neural differentiation in combination with the standard concentration of inhibitors might not be likely. To see how the cells would survive without the inhibitors, N2B27 alone was employed. Furthermore, the Burdon team has shown before that the third medium, i.e. the combination of N2B27 with reduced inhibitor concentrations (1.5µM CHIR99021 and 0.25µM PD0325901), is able to induce neural differentiation.
In order to investigate whether the amount of available oxygen might be of influence on the cell survival, one plate was kept at 37°C in 5% O2, the other plate was kept at 37°C in 21% O2. 
During the experiment, a half media change was performed every 2-3 days. Bright-field pictures of the cells were taken every 1-2 days (not shown). 
Within one day of plating cell death was observed in N2B27 and N2CHPD of both the plate kept at low and the plate kept at normal oxygen, however, the cells in N2CHPD seemed to survive a little bit better. The cells in N2B27 + 2i of the plates in both oxygen conditions expanded, although a fast number of cell death was present as well. The cell survival seemed to be a bit higher on the 5% O2 plate.
Six days after plating, all cells in N2B27 and N2CHPD had died. The cells in N2B27 + 2i of the two plates had reached a high confluency and therefore, the cells in N2B27 + 2i of each plate was passaged. Again CDB was replaced by TVP and the cells were spun down in GMEM. The cells in N2B27 + 2i on the plate kept in 5% O2 were passaged to three laminin coated wells on a 4-well plate, in a density of 2x104 cells/well. Cells were plated in the three different media (well 1: N2B27, well 2: N2B27 + 2i, well 3: N2B27 + 1.5µM CHIR99021 and 0.25µM PD0325901) and the plate was kept at 37°C in 5% O2. The cells in N2B27 + 2i on the plate kept in 21% O2 were passaged the exact same way to a plate which was kept at 37°C in 21% O2.
The cells plated down well after the passage. Nevertheless, the cells started to die off during the next days. Again, the cells only seemed to expand in N2B27 + 2i. The cells in N2CHPD appeared to survive better compared to the cells in N2B27. Cell survival seemed higher on the 5% O2 plate.
After 5 days, the cells in N2B27 + 2i of each plate were passaged again. Unfortunately, after this second passage the cells were dying as well. Overall, cell survival seemed to be best in N2B27 + 2i medium and at a low oxygen concentration. No differentiation was observed.
3.3.4 Neural differentiation using RIF4.1 and RIDA6.8
Feeder-free cell lines were also tested. A neural differentiation experiment was set up, using feeder-free cell lines RIF4.1 and RIDA6.8. The cells of each cell line were plated in a density of 5x103 cells/well on three laminin coated wells on a 4-well plate in the same three media applied in the previous experiment:
-Well 1: N2B27
-Well 2: N2B27 + 2i
-Well 3: N2B27 + 1.5µM CHIR99021 and 0.25µM PD0325901
Both plates were kept at 37°C in 5% O2, because the low oxygen concentration seemed to enhance cell survival in the previous experiment. 
The cells of  RIF4.1 cell line in N2B27 and N2CHPD started to die off, after plating down. The cells in N2B27 + 2i did expand. Cell survival was better in line RIDA6.8. However, cells started to die off as well. Especially in N2B27 and N2CHPD, the cell survival was low. No sign of differentiation was observed. 

























4.1 Analysis of PD0325901 titration samples by RT-PCR
The aim of this project was to investigate whether established rat ES cell neural differentiation induces midbrain specification and generation of mDA neurons. In order to develop cell replacement therapy for PD, many researchers have attempted to differentiate ES cells into mDA neurons. So far, dopaminergic neurons have been generated from primate, human and mouse ES cells.15 Rat ES cells are a relatively new source of stem cells, first derived in 2008.23, 27 The Burdon team is one of only a few in the world working on the differentiation of rat ES cells. They established neural differentiation of a Fisher 4.4 rat ES cell line, by adjusting the level of MEK/ERK inhibition by means of using a reduced concentration of CHIR99021 and applying different concentrations of PD0325901.(Unpublished data) During this project these PD0325901 titration samples were analysed by RT-PCR for the presence of midbrain marker expression.

The RT-PCR conditions for several markers of midbrain specification and mature mDA neurons were optimized. The optimization process consisted of applying different primer concentrations, different MgCl2 concentrations and different annealing temperatures. This method to find the optimal RT-PCR conditions for each marker is typically used in research.50 
The optimal conditions were determined by visual differences between the PCR products. This might, however, be a somewhat subjective manner to decide which condition is optimal as the differences between conditions are sometimes unclear. In the case of Lmx1b, non-specific PCR products were formed. During the first step of the optimization step, with the appliance of different primer concentrations, non-specific bands were visible. It is questionable whether the optimization should have proceeded. It might have been more precise to design new primers.

The optimized RT-PCR conditions were used in evaluating the PD0325901 titration samples for midbrain marker expression. The results of the RT-PCR analysis of the PD0325901 titration samples demonstrate that indeed markers of mDA neuronal specification were identified in rat ES cell derived neurons. 
The expression of pluripotency markers Oct4, Nanog, Rex1 and Klf4 seemed to be strongest in the 2,0 µM PD0325901 sample. This can be explained by the fact that PD0325901 is required for self-renewal and pluripotency of ES cells. As the concentration of PD0325901 lowered, the PCR bands of these four markers became gradually less clear and for the sample without any PD0325901 there was no band visible at all. This might be an indication for a higher level of cell differentiation, hence less pluripotency of the cells, in the samples with a lower concentration of PD0325901. 
The expression of Pax6, a pan-neuronal marker, showed just the opposite pattern. The visibility of the PCR bands gradually increased for the samples with lower concentrations of PD0325901. A PCR band was most clearly visible in the 0.25 µM PD0325901 sample, but no band was seen in the 0 µM PD0325901 sample. This expression pattern was confirmed by RT-PCR analysis of a different batch of cDNA samples during this project and researchers of the Burdon team have also observed this pattern before. As mentioned in the introduction, a possibility is that neural differentiation is enhanced by using low concentrations of PD0325901, and that in the absence of PD0325901 muscle differentiation is promoted, probably due to the effects of CHIR99021. CHIR99021 is a selective inhibitor of GSK3. In principal, GSK3 negatively affects substrate-mediated downstream signalling.51 Therefore, the inactivation of GSK3 usually results in the stimulation of certain cellular events.51 GSK3 is part of the Wnt signalling pathway.51 Wnts are secreted glycoproteins that serve as important signalling molecules in development.51 Wnt signalling has been associated with many processes, for instance bone development, angiogenesis, lipid and glucose metabolism, stem cell renewal and differentiation, and myogenesis.51 It is known that GSK3 activity is suppressed by Wnt.51 The inhibition of GSK3 by CHIR99021 could be equivalent to Wnt signalling, which might explain muscle differentiation of ES cells exposed only to CHIR99021 and not PD0325901.
The markers Otx2, Lmx1b and En2, which were employed in the RT-PCR analysis of the PD0325901 titration samples, are early markers of midbrain specification. All of these three markers were clearly identified in the PD0325901 titration samples. Otx2 and En2 both showed an expression pattern quite similar to the pattern of the pluripotency markers. The PCR bands came up strongly in the samples with higher concentrations of PD0325901, and then gradually decreased in visibility as the PD0325901 concentrations were lower. This result was also confirmed by RT-PCR analysis of a different batch of cDNA samples. The pattern might be explained by the early expression of these markers in the differentiation process. The samples with higher concentrations of PD0325901 showed a very clear expression of pluripotency markers, which might indicate a low level of differentiation. Otx2 and En2, however, are very early markers of midbrain specification and might already be expressed at that stage, despite the high PD0325901 concentrations that inhibit cell differentiation. Conversely, Lmx1b expression increased as the PD0325901 concentration was lowered. A possible explanation for this observation might be that Lmx1b is a marker that comes to expression slightly later than Otx2 and En2. It might be that this marker is not present in the samples with high concentrations of PD0325901, where cell differentiation is strongly inhibited, but comes to expression at a somewhat proceeded stage in differentiation, which means in the presence of lower PD0325901 concentrations. Otx2 and Lmx1b both show expression in the 0 µM PD0325901 sample and Otx2 and En2 seem to be expressed in the sample with undifferentiated rat ES cells. Expression of midbrain specification markers in these samples might seem unexpected, as it is very unlikely that a significant level of neural differentiation has occurred in undifferentiated ES cells or in an environment that does not promote differentiation into a neural cell fate. Possibly the fact that these markers are not specific only for midbrain development might offer a plausible explanation. For example, Otx2 does not only come to expression in the fore- and hindbrain, but is found to be expressed in the developing human retina as well.52 The expression of En2 is not limited to the midbrain-hindbrain border, but En2 is for instance also expressed in some other brain areas and the mandibular arch.53 
In this RT-PCR analysis of PD0325901 titration samples mid-stage developmental markers of midbrain specification are represented by Msx1, Foxa2 and Nurr1. Msx1 and Foxa2 are both clearly expressed in the PD0325901 titration samples. It should, however, be taken into account that these markers are highly unspecific. Besides its expression in the brain, Msx1 is also expressed in the skeleton, heart, teeth and limbs.54-57 Foxa2 expression reaches from several brain structures and olfactory epithelium, to liver, lung, pancreas, stomach, intestine, prostate, bladder, kidney, vagina, uterus, seminal and coagulating glands.58 Nurr1 on the other hand seems somewhat more specific to mDA neurons, but is also expressed in some other regions of the nervous system.59, 60 It is very encouraging to see that expression of this late mid-marker of midbrain specification can be observed from the RT-PCR analysis of the PD0325901 titration samples. Moreover, the expression of Foxa2 and Nurr1 was confirmed by RT-PCR analysis of a different batch of cDNA samples.
The markers Otx2, En2 and Msx1 appear in the rat ES cell samples of the RT-PCR analysis. As mentioned before, the inhibition of GSK3 by CHIR99021 seems to be equivalent to Wnt signalling. It has been found that GSK3 inhibition is able to induce mDA differentiation, by mimicking several effects of Wnts.61 Moreover, a link exists between the expression of the markers Otx2, En2 and Msx1 and Wnt signalling.62-64 Therefore, it might be that the presence of these markers in rat ES cell samples is a side-effect of GSK3 inhibition by CHIR99021 in a 2i culture.
Although Pitx3 expression level is low, the observation that both late markers of midbrain specification, Pitx3 and TH, seem to be expressed in the PD0325901 titration samples is most encouraging. Besides the expression of Pitx3 in late midbrain development, its expression in skeletal muscles has also been reported.65 TH, an essential enzyme in the biosynthesis of dopamine, is highly specific to dopaminergic neurons. The observation that TH seems to be expressed in the PD0325901 titration samples is, therefore, a very promising result. 
The results of the RT-PCR analysis of the PD0325901 titration samples show that markers of midbrain specification and mDA neurons have been identified in the samples. It must be strongly taken into account that the detection of the expression of a single marker by RT-PCR, does not necessarily have to indicate midbrain specification of cells in the sample. As has been mentioned before, most markers are not specific for midbrain or mDA neurons, but come to expression in other regions and cells of the body as well. For that reason, only the combination of expression patterns of several midbrain or mDA neuronal markers might be an indication for cell differentiation towards a midbrain or mDA neuronal fate.
RT-PCR is a semi-quantitative technique. Using this technique has its limitations, as no valid quantitative measures can be made. A much more accurate method that gains quantitative data is real-time PCR or real-time RT-PCR.66 This technique collects data during the PCR process as it occurs.66 The amplification of PCR product and its detection is combined into a single step, through the usage of several different fluorescent chemistries that associate the concentration of PCR product to fluorescence intensity.66 The use of real-time RT-PCR has some significant advantages, since it produces quantitative data with a high accuracy and post-amplification manipulation is not needed.66

4.2 Neural differentiation experiments
An attempt was made to differentiate rat ES cells into a neuronal and possibly even to a mDA neuronal fate. Unfortunately, as the cells kept dying, no conclusions can be drawn from this experiment. 
Effort was put into enhancing the survival of the cells. Several cell densities and different media were tried. Although the cells seemed to survive longer at a higher density, in order to induce differentiation the cells must not be too confluent, and therefore an intermediate cell density was chosen for the following experiments. The survival of the cells in N2B27 + 2i medium seemed better than survival of the cells in the other two media. This might be due to the fact that this medium promotes cell survival and expansion. However, the use of N2B27 + 2i medium for a differentiation experiment is not favourable, since this medium inhibits cell differentiation. 
The cells were also exposed to different concentrations of oxygen. Cell in vitro are exposed to oxygen levels that are usually much higher than the in vivo situation. It has already been found that exposing cells in vitro to low oxygen concentration can enhance cell survival and even neural differentiation. Rodrigues et al. studied the effect of low oxygen concentrations on mouse ES cell derived neural stem cells.67 They demonstrated that 2-5% O2 led to total cell numbers about twice as high compared to the cell numbers observed under 20% O2.67 Stacpoole et al. investigated whether an oxygen level of 3% permits the development of neural precursor cells from human ES cells and whether these neural precursor cells are able to undergo regional specification and functional maturation.68 They found that at 3% O2, the cells exhibited a robust and efficient neural conversion.68 The neural precursor cells derived under 3% O2 were differentiated and  readily specified into spinal motor neurons and mDA neurons.68 
During this project, the cells seemed to survive better at low oxygen levels as well, although this is purely based on observations. No real statements can be made, as no cell counts were performed. 
To rule out a possible negative influence from the feeder cells on the rat ES cells, feeder-free cell lines were applied. But even these feeder-free cells did not survive very well, suggesting that the cell death was not solely due to the indirect effect of a sub-standard feeder cell layer. 
The key to the answer of the question why the cells kept dying might be found in the plates that were used for the differentiation experiments. Due to an unfortunate mistake, ultra-low-attachments plates were used, which are normally applied for the culture of embryoid bodies. This means that the cells could not properly attach to the plates. A simple solution to a seemingly complicated mystery! 

4.3 Future directions
The ultimate goal of the differentiation of rat ES cells into mDA neurons is to create a pool of cells that can be utilised for the screening of new drugs or as cell replacement therapy for PD. Such a cell replacement therapy requires a pure population of mDA neurons. Therefore, the efficiency of TH expressing neuron generation needs to be enhanced. 
As has been described in the introduction, two main signals are important for the induction of dopaminergic neurons, namely Fgf8 and Shh. Fgf8 induces anterior-posterior identity of the midbrain and plays a role in defining midbrain cell fate.33, 34 Shh is significant for dorsal-ventral patterning of the midbrain.33, 34 Several studies have shown that application of Fgf8 and Shh increases the yield of ES cell derived TH expressing neurons. Lee et al. demonstrated that the differentiation of mouse ES cells into dopaminergic neurons can be promoted by applying Fgf8 and Shh.41 They found that the appliance of Fgf8 and Shh during a certain stage in the differentiation process of mouse ES cells leads to a more than twofold increase in the number of TH expressing cells.41 Yan et al. showed that administration of Fgf8 and Shh leads to efficient generation of dopaminergic neurons from human ES cells.69 They discovered that the time window of Fgf8 and Shh application is important in determining the specification of the human ES cells into midbrain or forebrain dopaminergic neurons.69 Early exposure to Fgf8 throughout the process of neuroepithelial specification leads the cells to a midbrain fate and mDA neuron differentiation.69 Exposure to Fgf8 and Shh after a certain time point promotes differentiation into dopaminergic neurons, but mainly with a forebrain phenotype.69 
Chang et al. reported the direct reprogramming of  rat embryonic fibroblasts and rat neural precursor cells into iPS cells.44 They demonstrated the efficient differentiation of these rat iPS cells into midbrain-like dopaminergic neurons.44 In the presence of Shh, Fgf8 and ascorbic acid, the differentiation of rat fibroblast derived iPS cells led to high yields of neurons (about 82% of total cells) and dopaminergic neurons (about 9% of neurons).44 These TH expressing neurons also co-expressed the midbrain markers Pitx3 and En1, which indicates a midbrain dopaminergic phenotype.44 
A proposition for a future experiment, following this current project, could be to investigate whether the generation of mDA neurons can be enhanced by the appliance of Shh and Fgf8 in the differentiation protocol for rat ES cell derived mDA neurons. For instance, rat ES cells could be plated in a medium that has been shown to promote differentiation into a mDA neuronal fate, such as N2B27 + 1.5μM CHIR99021 + 0.25μM PD0325901. One group of rat ES cells would be kept in this medium without any further application of other substances, and this group would represent the control group. Shh and Fgf8 would be administered on different time points to other groups of rat ES cells. The results of this experiment could be analysed by real-time RT-PCR and immunohistochemistry. Real-time RT-PCR analysis could be performed for several markers of midbrain specification and would give quantitative measurements. Immunohistochemistry could be executed for a neuron marker, Tuj1, and a marker of dopaminergic neurons, TH. Using these two markers would give the opportunity to calculate the percentage of TH expressing neurons from the percentage of total neurons. 
The results of this possible experiment would provide the answer to two important questions. First, does the appliance of Shh and Fgf8 enhance the generation of mDA neurons from rat ES cells? And second, at which time point is the appliance of Shh and Fgf8 most effective for the differentiation of rat ES cells into mDA neurons?
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Appendix 2: RT-PCR conditions for primers

βactin2:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-1.5mM MgCl2				-58°C for 40 sec.	30 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.4µM forward primer			-72°C for 10 min.	
-0.4µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)
-0.5µl Taq polymerase (5 units/µl)

Otx2:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-2.0mM MgCl2				-63°C for 40 sec.	32 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.8µM forward primer			-72°C for 10 min.	
-0.8µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)
-0.5µl Taq polymerase (5 units/µl)

TH:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-1.5mM MgCl2				-52°C for 40 sec.	32 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.2µM forward primer			-72°C for 10 min.	
-0.2µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)
-0.5µl Taq polymerase (5 units/µl)

Pitx3:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-1.5mM MgCl2				-61°C for 40 sec.	32 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.2µM forward primer			-72°C for 10 min.	
-0.2µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)
-0.5µl Taq polymerase (5 units/µl)

En2, Pax6, Nurr1, Foxa2:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-1.5mM MgCl2				-50°C for 40 sec.	32 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.2µM forward primer			-72°C for 10 min.	
-0.2µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)
-0.5µl Taq polymerase (5 units/µl)

Lmx1b:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-1.5mM MgCl2				-61°C for 40 sec.	32 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.8µM forward primer			-72°C for 10 min.	
-0.8µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)
-0.5µl Taq polymerase (5 units/µl)

Msx1:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-2.0mM MgCl2				-61°C for 40 sec.	32 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.8µM forward primer			-72°C for 10 min.	
-0.8µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)






Rex1, Oct4, Nanog, Klf4:
50μl reaction volume:				PCR amplification:
-ddH2O					-94°C for 2 min.	
-x1 Buffer					-94°C for 30 sec.
-1.5mM MgCl2				-50°C for 40 sec.	32 cycles
-0.4mM dNTPs				-72°C for 40 sec.
-0.2µM forward primer			-72°C for 10 min.	
-0.2µM reverse primer			-4°C forever
-2μl cDNA (200ng/µl)
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